Literature DB >> 22160086

The hepcidin-ferroportin system as a therapeutic target in anemias and iron overload disorders.

Tomas Ganz1, Elizabeta Nemeth.   

Abstract

The review summarizes the current understanding of the role of hepcidin and ferroportin in normal iron homeostasis and its disorders. The various approaches to therapeutic targeting of hepcidin and ferroportin in iron-overload disorders (mainly hereditary hemochromatosis and β-thalassemia) and iron-restrictive anemias (anemias associated with infections, inflammatory disorders, and certain malignancies, anemia of chronic kidney diseases, and iron-refractory iron-deficiency anemia) are also discussed.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22160086      PMCID： PMC4034574          DOI： 10.1182/asheducation-2011.1.538

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN： 1520-4383


  37 in total

Review 1.  Detection, evaluation, and management of iron-restricted erythropoiesis.

Authors:  Lawrence Tim Goodnough; Elizabeta Nemeth; Tomas Ganz
Journal:  Blood       Date:  2010-09-08       Impact factor: 22.113

2.  Heparin: a potent inhibitor of hepcidin expression in vitro and in vivo.

Authors:  Maura Poli; Domenico Girelli; Natascia Campostrini; Federica Maccarinelli; Dario Finazzi; Sara Luscieti; Antonella Nai; Paolo Arosio
Journal:  Blood       Date:  2010-11-12       Impact factor: 22.113

Review 3.  Anemia, ineffective erythropoiesis, and hepcidin: interacting factors in abnormal iron metabolism leading to iron overload in β-thalassemia.

Authors:  Sara Gardenghi; Robert W Grady; Stefano Rivella
Journal:  Hematol Oncol Clin North Am       Date:  2010-10-15       Impact factor: 3.722

4.  Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease.

Authors:  Soken-Nakazawa J Song; Naohisa Tomosugi; Hiroshi Kawabata; Takayuki Ishikawa; Teppei Nishikawa; Kazuyuki Yoshizaki
Journal:  Blood       Date:  2010-07-19       Impact factor: 22.113

5.  Evidence for distinct pathways of hepcidin regulation by acute and chronic iron loading in mice.

Authors:  Emilio Ramos; Léon Kautz; Richard Rodriguez; Michael Hansen; Victoria Gabayan; Yelena Ginzburg; Marie-Paule Roth; Elizabeta Nemeth; Tomas Ganz
Journal:  Hepatology       Date:  2011-04       Impact factor: 17.425

6.  Tmprss6 is a genetic modifier of the Hfe-hemochromatosis phenotype in mice.

Authors:  Karin E Finberg; Rebecca L Whittlesey; Nancy C Andrews
Journal:  Blood       Date:  2011-02-25       Impact factor: 22.113

7.  The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation.

Authors:  Gaël Nicolas; Caroline Chauvet; Lydie Viatte; Jean Louis Danan; Xavier Bigard; Isabelle Devaux; Carole Beaumont; Axel Kahn; Sophie Vaulont
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

Review 8.  Hepcidin and disorders of iron metabolism.

Authors:  Tomas Ganz; Elizabeta Nemeth
Journal:  Annu Rev Med       Date:  2011       Impact factor: 13.739

9.  Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation.

Authors:  Andrea U Steinbicker; Chetana Sachidanandan; Ashley J Vonner; Rushdia Z Yusuf; Donna Y Deng; Carol S Lai; Kristen M Rauwerdink; Julia C Winn; Borja Saez; Colleen M Cook; Brian A Szekely; Cindy N Roy; Jasbir S Seehra; Gregory D Cuny; David T Scadden; Randall T Peterson; Kenneth D Bloch; Paul B Yu
Journal:  Blood       Date:  2011-03-10       Impact factor: 22.113

10.  Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease.

Authors:  David A Weinstein; Cindy N Roy; Mark D Fleming; Massimo F Loda; Joseph I Wolfsdorf; Nancy C Andrews
Journal:  Blood       Date:  2002-06-28       Impact factor: 22.113
View more
  44 in total

Review 1.  Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries.

Authors:  Hilmar K Lückhoff; Frederik C Kruger; Maritha J Kotze
Journal:  World J Hepatol       Date:  2015-05-28

2.  Reducing iron accumulation: A potential approach for the prevention and treatment of postmenopausal osteoporosis.

Authors:  Bin Chen; Guang-Fei Li; Ying Shen; X I Huang; You-Jia Xu
Journal:  Exp Ther Med       Date:  2015-05-08       Impact factor: 2.447

3.  An insight into the relationships between prohepcidin, iron deficiency anemia, and interleukin-6 values in pediatric Helicobacter pylori gastritis.

Authors:  Nagehan Emiralioglu; Idil Yenicesu; Sinan Sari; Odul Egritas; Aylar Poyraz; Ozge Tugce Pasaoglu; Bulent Celik; Buket Dalgic
Journal:  Eur J Pediatr       Date:  2015-01-09       Impact factor: 3.183

4.  Hepcidin-dependent and hepcidin-independent regulation of erythropoiesis in a mouse model of anemia of chronic inflammation.

Authors:  Jacqueline M Langdon; Saiah C Yates; Laurette K Femnou; Bryan J McCranor; Chris Cheadle; Qian-Li Xue; Sophie Vaulont; Curt I Civin; Jeremy D Walston; Cindy N Roy
Journal:  Am J Hematol       Date:  2014-02-24       Impact factor: 10.047

Review 5.  Regulation of cellular iron metabolism and its implications in lung cancer progression.

Authors:  Wei Xiong; Li Wang; Fenglei Yu
Journal:  Med Oncol       Date:  2014-05-27       Impact factor: 3.064

6.  Iron overload in transfusion-dependent survivors of hemoglobin Bart's hydrops fetalis.

Authors:  Ali Amid; Shiyi Chen; Uma Athale; Karen Charpentier; Manuela Merelles-Pulcini; Isaac Odame; Melanie Kirby-Allen
Journal:  Haematologica       Date:  2018-01-25       Impact factor: 9.941

7.  Understanding Iron Metabolism: Lessons from Transfusion-dependent Thalassemia.

Authors:  Murtadha Al-Khabori; Shahina Daar
Journal:  Oman Med J       Date:  2018-01

8.  Glycol-split nonanticoagulant heparins are inhibitors of hepcidin expression in vitro and in vivo.

Authors:  Maura Poli; Michela Asperti; Annamaria Naggi; Natascia Campostrini; Domenico Girelli; Michela Corbella; Marina Benzi; Celine Besson-Fournier; Helene Coppin; Federica Maccarinelli; Dario Finazzi; Paolo Arosio
Journal:  Blood       Date:  2014-01-07       Impact factor: 22.113

Review 9.  Management of the Jehovah's Witness in Obstetrics and Gynecology: A Comprehensive Medical, Ethical, and Legal Approach.

Authors:  Burak Zeybek; Andrew M Childress; Gokhan S Kilic; John Y Phelps; Luis D Pacheco; Michele A Carter; Mostafa A Borahay
Journal:  Obstet Gynecol Surv       Date:  2016-08       Impact factor: 2.347

10.  Negative feedback regulation of the yeast CTH1 and CTH2 mRNA binding proteins is required for adaptation to iron deficiency and iron supplementation.

Authors:  Mar Martínez-Pastor; Sandra V Vergara; Sergi Puig; Dennis J Thiele
Journal:  Mol Cell Biol       Date:  2013-03-25       Impact factor: 4.272
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.